STOCK TITAN
  1. Home
  2. News
  3. MRK

Merck & Co Inc - MRK STOCK NEWS

Welcome to our dedicated news page for Merck & Co (Ticker: MRK), a resource for investors and traders seeking the latest updates and insights on Merck & Co.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Merck & Co's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Merck & Co's position in the market.

News
Merck and Eisai Provide Update on Phase 3 LEAP-010 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Patients With Certain Types of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Rhea-AI Summary
Merck and Eisai provide update on Phase 3 trial for KEYTRUDA and LENVIMA combination in head and neck cancer
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.69%
Tags
clinical trial
-
News
LYNPARZA® (olaparib) Plus Abiraterone and Prednisone or Prednisolone Approved in Japan for the Treatment of BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer
Rhea-AI Summary
LYNPARZA combination approved in Japan for BRCA-mutated castration-resistant prostate cancer with distant metastasis
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.66%
Tags
none
-
News
Merck Announces WELIREG® (belzutifan) Phase 3 LITESPARK-005 Trial Met Primary Endpoint of Progression-Free Survival in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma
Rhea-AI Summary
WELIREG shows positive Phase 3 results in RCC trial with statistically significant improvements in PFS and ORR compared to everolimus. OS results inconclusive. Safety profile consistent with previous studies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.26%
Tags
clinical trial
News
Merck Employee Talks Pride, Pediatrics and Parenting
Rhea-AI Summary
Merck & Co., Inc. - Dr. Rodney Finalle, a pediatrician and global director of medical affairs, shares his personal journey as a member of the LGBTQ+ community and the support he received from his workplace and community. Merck's partnership with a program matching professionals with nonprofit boards allowed Finalle to join the board of a local LGBTQ+ community center.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.06%
Tags
none
-
News
Merck Is Harnessing Innovation To Reach Indigenous Communities
Rhea-AI Summary
Merck & Co., Inc. - Alaska partners with University of Alaska and drone provider to demonstrate drone delivery of medicines to remote villages, showcasing innovative solutions for increasing access to lifesaving pharmaceuticals in extreme weather and terrain. The project aims to expand access to medicines in remote areas, addressing the challenges faced by people living in Alaska's 240 remote villages and communities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.3%
Tags
none
-
News
Anixa Biosciences Announces Opening of Enrollment for Keytruda® Arm in Ongoing Breast Cancer Vaccine Clinical Trial
Rhea-AI Summary
Anixa Biosciences, Inc. (ANIX) announces the enrollment of subjects in a treatment arm evaluating the combination of its breast cancer vaccine with Keytruda (pembrolizumab) by its partner, Cleveland Clinic. The trial aims to determine if the vaccine/Keytruda combination increases immune response against triple negative breast cancer (TNBC), with potential synergistic effects. The company looks forward to the presentation of updated data from this trial at the San Antonio Breast Cancer Symposium in December.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.27%
Tags
clinical trial
News
U.S. FDA Approves Merck’s ERVEBO® (Ebola Zaire Vaccine, Live) for Use in Children 12 Months of Age and Older
Rhea-AI Summary
Merck (NYSE: MRK) has received FDA approval for the expanded indication of ERVEBO, a vaccine to prevent Zaire ebolavirus disease in individuals 12 months and older. The vaccine was previously approved for those 18 and older. The European Medicines Agency's Committee also recommended expanded approval for individuals 1 year and older. ERVEBO has a contraindication for individuals with a history of severe allergic reactions to any component of the vaccine. The vaccine's effectiveness when administered with other medications is unknown. Merck has also confirmed an agreement with UNICEF to establish the world’s first global Ebola vaccine stockpile with ERVEBO.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.03%
Tags
fda approval
-
News
Merck Announces Second-Quarter 2023 Financial Results
Rhea-AI Summary
Merck reports Q2 2023 financial results with total worldwide sales of $15.0 billion, an increase of 3% from Q2 2022. Key highlights include growth in KEYTRUDA and GARDASIL sales, decline in LAGEVRIO sales, and a GAAP loss per share of $2.35.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.28%
Tags
earnings
-
News
Merck Announces Phase 3 KEYNOTE-756 Trial Met Primary Endpoint of Pathological Complete Response (pCR) Rate in Patients With High-Risk, Early-Stage ER+/HER2- Breast Cancer
Rhea-AI Summary
Merck (MRK) announces positive Phase 3 study results for KEYTRUDA in combination with chemotherapy for high-risk, early-stage ER-positive, HER2-negative breast cancer, showing a significant improvement in pCR rate compared to neoadjuvant placebo plus chemotherapy. The trial will continue to evaluate the other primary endpoint of event-free survival. Safety profile consistent with previous studies. Results to be presented at upcoming medical meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.02%
Tags
clinical trial
News
Merck Announces V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Met Key Immunogenicity and Safety Endpoints in Two Phase 3 Trials
Rhea-AI Summary
Merck (NYSE: MRK) Announces Positive Phase 3 Results for V116 Pneumococcal Vaccine, Demonstrating Strong Immune Responses in Adults
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.75%
Tags
clinical trial
Stock MRK logo
Merck & Co Inc

NYSE:MRK

MRK Rankings

#24 Ranked by Market Cap
#1895 Ranked by Stock Gains
#1274 Ranked by Dividends

MRK Stock Data

318.50B
2.53B
0.05%
78.56%
0.77%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Kenilworth

About MRK

Merck & Co., Inc. is an American multinational pharmaceutical company headquartered in Rahway, New Jersey, and is named for Merck Group, founded in Germany in 1668, of whom it was once the American arm. The company does business as Merck Sharp & Dohme or MSD outside the United States and Canada.